Dublin, Ireland (PRWEB) March 20, 2013
As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of decreasing hormone levels have come to the forefront as a quality-of-life issue for patients and their families.
For the past two decades, the healthcare industry has responded to this clinical need by developing, testing and marketing hormone replacement therapy (HRT) products. Because of their ease-of-use and dosing characteristics, drug developers are continuing to turn to transdermal delivery systems for HRT products. There are more than 40 million post-menopausal women in the United States alone, and this group is expected to grow by 50% by 2020. With the aging of the population worldwide, conditions and diseases such as menopause, osteoporosis and heart disease, which may benefit from hormone replacement therapy, are expected to become significantly more prevalent. The industry continues to attract interest in the form of new participants and products.
While the global market continues to be dominated by the FDA-approved HRT products of major pharmaceutical firms, regional markets are a bit more competitive, and present unique challenges to transdermal HRT sector participants.
For more information please visit http://www.researchandmarkets.com/research/c4mvd9/transdermal
Research and Markets
Laura Wood, Senior Manager.